Filtered By:
Source: Thrombosis and Haemostasis
Condition: Bleeding

This page shows you your search results in order of relevance. This is page number 9.

Order by Relevance | Date

Total 164 results found since Jan 2013.

Dual Pathway Inhibition with Low-Dose Direct Factor Xa Inhibition after Acute Coronary Syndromes-Why Is It Not Used in Clinical Practice?
This article discusses the value and problems of adding low-dose rivaroxaban to anti-platelet therapy as secondary prevention measure after an acute myocardial infarction. It will describe the pros and cons of intensified anti-platelet therapy versus dual pathway inhibition and give recommendations for different patient groups in clinical practice. PMID: 30103248 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - August 13, 2018 Category: Hematology Authors: Zeymer U, Schrage B, Westermann D Tags: Thromb Haemost Source Type: research

Platelet Reactivity and Early Outcomes after Transfemoral Aortic Valve Implantation.
Abstract Beyond thromboembolic events, peri-procedural bleeding remains one of the most frequent complications after transcatheter aortic valve implantation (TAVI). The majority of TAVI patients receive a dual anti-platelet treatment (DAPT) regimen. This analysis from the EVERY-TAVI register database aimed to analyse whether the level of on-treatment adenosine diphosphate-induced platelet reactivity predicts early outcomes at 30 days after TAVI. A total of 146 consecutive TAVI patients on DAPT who underwent platelet function testing with the Multiplate analyser were included here. Definition of bleeding events was...
Source: Thrombosis and Haemostasis - September 20, 2018 Category: Hematology Authors: Gross L, Jochheim D, Nitschke T, Baquet M, Orban M, Holdt L, Zadrozny M, Hagl C, Teupser D, Bauer A, Massberg S, Mehilli J, Sibbing D Tags: Thromb Haemost Source Type: research

The Non-Vitamin K Antagonist Oral Anticoagulants in Heart Disease: Section V-Special Situations.
Abstract Non-vitamin K antagonist oral anticoagulants (NOACs) include dabigatran, which inhibits thrombin, and apixaban, betrixaban, edoxaban and rivaroxaban, which inhibit factor Xa. In large clinical trials comparing the NOACs with the vitamin K antagonist (VKA) warfarin, dabigatran, apixaban, rivaroxaban and edoxaban were at least as effective for stroke prevention in atrial fibrillation and for treatment of venous thromboembolism, but were associated with less intracranial bleeding. In addition, the NOACs are more convenient to administer than VKAs because they can be given in fixed doses without routine coagu...
Source: Thrombosis and Haemostasis - January 1, 2019 Category: Hematology Authors: De Caterina R, Ageno W, Agnelli G, Chan NC, Diener HC, Hylek E, Raskob GE, Siegal DM, Verheugt FWA, Lip GYH, Weitz JI Tags: Thromb Haemost Source Type: research

Dual Antiplatelet or Dual Antithrombotic Therapy for Secondary Prevention in High-Risk Patients with Stable Coronary Artery Disease?
Abstract Antithrombotic treatment is a key component of secondary prevention following acute coronary syndromes (ACS). Although dual antiplatelet therapy is standard therapy post-ACS, duration of treatment is the subject of ongoing debate. Prolonged dual antiplatelet therapy in high-risk patients with history of myocardial infarction reduced the risk of recurrent myocardial infarction, stroke or cardiovascular death. Similarly, in patients with stable coronary artery disease, two-thirds of whom had a history of myocardial infarction, dual antithrombotic therapy with very-low-dose rivaroxaban and aspirin also resul...
Source: Thrombosis and Haemostasis - March 4, 2019 Category: Hematology Authors: Sumaya W, Geisler T, Kristensen SD, Storey RF Tags: Thromb Haemost Source Type: research

Hemostatic Genes Exhibit a High Degree of Allele-Specific Regulation in Liver.
CONCLUSION:  Our study provides a comprehensive ASE analysis of hemostatic genes and insights into the regulation of hemostatic genes in human liver. PMID: 31035302 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - April 28, 2019 Category: Hematology Authors: Olsson Lindvall M, Hansson L, Klasson S, Davila Lopez M, Jern C, Stanne TM Tags: Thromb Haemost Source Type: research

Platelet surface expression of cyclophilin A is associated with increased mortality in patients with symptomatic coronary artery disease.
CONCLUSION: CyPA platelet surface expression is associated with mortality whereas CyPA PPIA rs6850 is associated with recurrent MI in patients with symptomatic CAD. CyPA might offer a new biomarker for risk stratification and tailoring therapies in patients with cardiovascular disease. PMID: 31519036 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - September 12, 2019 Category: Hematology Authors: Rath D, von Ungern-Sternberg S, Heinzmann D, Sigle M, Monzien M, Horstmann K, Schaeffeler E, Winter S, Müller K, Groga-Bada P, Zdanyte M, Borst O, Zernecke A, Gawaz M, Martus P, Schwab M, Geisler T, Seizer P Tags: J Thromb Haemost Source Type: research

Engineered Micro- and Nanoparticles for Fibrinolysis.
Abstract Fibrinolytic agents including plasmin and plasminogen activators improve outcomes in acute ischemic stroke and thrombosis by recanalizing occluded vessels. In the decades since their introduction into clinical practice, several limitations of have been identified both in terms of efficacy and bleeding risk associated with these agents. Engineered nano- and microparticles address some of these limitations by improving circulation time, reducing inhibition and degradation in circulation, accelerating recanalization, improving targeting to thrombotic occlusions, and reducing off-target effects; however, many...
Source: Thrombosis and Haemostasis - September 15, 2019 Category: Hematology Authors: Disharoon D, Marr DWM, Neeves KB Tags: J Thromb Haemost Source Type: research

Prophylaxis of Venous Thromboembolism after Hospital Discharge in Internal Medicine: Findings from the Observational FADOI-NoTEVole Study.
CONCLUSION:  In this study, one in five patients discharged from an Italian IMU received prophylaxis for VTE. The perceived thrombotic risk is significantly related to the use of prophylaxis. PMID: 31634959 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - October 20, 2019 Category: Hematology Authors: Squizzato A, Agnelli G, Campanini M, Dentali F, Agnelli F, Bonizzoni E, Franco A, Gallo A, Gussoni G, Nitti C, Triolo G, Valerio A, Ventrella F, Fontanella A, FADOI-NoTEVole Study Group Tags: Thromb Haemost Source Type: research

Lower versus Standard INR Targets in Atrial Fibrillation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
CONCLUSION:  Moderate quality evidence suggests lower INR targets reduce bleeding but increase thromboembolism in AF. The data are dominated by East-Asian studies, limiting generalizability to Western populations. Until higher quality data demonstrate otherwise, an INR range of 2 to 3 should remain standard for thromboembolic prophylaxis in AF. PMID: 31940677 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - January 14, 2020 Category: Hematology Authors: Pandey AK, Xu K, Zhang L, Gupta S, Eikelboom J, Cook O, McIntyre WF, Lopes RD, Crowther M, Belley-Côté EP, Whitlock RP Tags: Thromb Haemost Source Type: research

Potent and rapid reversal of the von Willebrand Factor Inhibitor Aptamer BT200.
CONCLUSIONS: The results of this study demonstrate that BT101 is an effective reversal agent for BT200. PMID: 32275107 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - April 9, 2020 Category: Hematology Authors: Zhu S, Gilbert JC, Liang Z, Kang D, Li M, Tarantino PM, Jilma B Tags: J Thromb Haemost Source Type: research

Evaluation of Oral Factor Xa inhibitor-associated Extracranial Bleeding Reversal with Andexanet alfa.
CONCLUSION: We report poor overall outcomes, a low rate of hemostatic effectiveness, and a high rate of ischemic complications and mortality in this retrospective analysis of oral FXa inhibitor reversal with andexanet alfa for extracranial bleeds. More rigorous epidemiological, and ideally randomized studies are needed to determine the role of andexanet alfa for FXa inhibitor-associated bleeding for extracranial hemorrhages, where large variation in severity and presentation exists. PMID: 32738161 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - July 31, 2020 Category: Hematology Authors: Nederpelt CJ, Naar L, Sylvesterc KW, Barra ME, Roberts RJ, Velmahos GV, Kaafarani HMA, Rosenthal MG, King DR Tags: J Thromb Haemost Source Type: research

Bleeding Complications Drive In-Hospital Mortality of Patients with Atrial Fibrillation after Transcatheter Aortic Valve Replacement.
CONCLUSION:  The present study demonstrates that the incidence of bleeding defines the in-hospital outcome of patients with AF after TF-TAVR. Thus, the periprocedural phase demands particular care in bleeding prevention. PMID: 32828074 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - August 21, 2020 Category: Hematology Authors: Lother A, Kaier K, Ahrens I, Bothe W, Wolf D, Zehender M, Bode C, von Zur Mühlen C, Stachon P Tags: Thromb Haemost Source Type: research

Edoxaban versus Warfarin in Patients with Atrial Fibrillation at the Extremes of Body Weight: An Analysis from the ENGAGE AF-TIMI 48 Trial.
CONCLUSION:  Patients with LBW in ENGAGE AF-TIMI 48 had in general a more fragile clinical status and poorer international normalized ratio control. The pharmacokinetic/pharmacodynamic profile of edoxaban was consistent across extremes of BW, resulting in similar efficacy compared with warfarin, while major or clinically relevant non-MB and net outcomes were most favorable with edoxaban as compared to warfarin in LBW patients. PMID: 32920808 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - September 12, 2020 Category: Hematology Authors: Boriani G, Ruff CT, Kuder JF, Shi M, Lanz HJ, Antman EM, Braunwald E, Giugliano RP Tags: Thromb Haemost Source Type: research

Novel Bleeding Risk Score for Patients with Atrial Fibrillation on Oral Anticoagulants, including Direct Oral Anticoagulants.
CONCLUSION: In this prospective cohort study of AF patients and predominantly DOAC users, we successfully derived a bleeding risk prediction model with good calibration and discrimination. PMID: 33501722 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - January 27, 2021 Category: Hematology Authors: Adam L, Feller M, Syrogiannouli L, Del-Giovane C, Donzé J, Baumgartner C, Segna D, Floriani C, Roten L, Fischer U, Aeschbacher S, Moschovitis G, Schläpfer J, Shah D, Amman P, Kobza R, Schwenkglenks M, Kühne M, Bonati L, Beer J, Osswald S, Conen D, Auje Tags: J Thromb Haemost Source Type: research

Impact of Transcatheter Aortic Valve Implantation on Thrombin Generation and Platelet Function
CONCLUSION: In this pilot study, we were able to demonstrate that thrombin generation is significantly increased early after TAVI, while platelet function is not affected. Increased thrombin concentrations may contribute to the high risk of postprocedural thromboembolic events. This leads to the hypothesis that extended peri-interventional anticoagulation early after TAVI may be an approach to reduce thromboembolic events.PMID:33759144 | DOI:10.1055/s-0041-1725190
Source: Thrombosis and Haemostasis - March 24, 2021 Category: Hematology Authors: Philipp Mourikis Lisa Dannenberg Saif Zako Carolin Helten Ren é M'Pembele Hannah Richter Thomas Hohlfeld Christian Jung Tobias Zeus Malte Kelm Verena Veulemans Amin Polzin Source Type: research